Welcome to our dedicated page for Neogenomics news (Ticker: NEO), a resource for investors and traders seeking the latest updates and insights on Neogenomics stock.
NeoGenomics, Inc. reports developments in oncology diagnostic testing, cancer genetics and information services. The company serves oncologists, pathologists, hospital systems, academic centers and pharmaceutical firms through cancer-focused laboratory testing, professional interpretation, clinical trial and research services, validation laboratory services and oncology data solutions.
Recurring news themes include clinical revenue trends, next-generation sequencing growth, reimbursement and coverage decisions, and additions to the company’s testing menu. Updates also cover products such as PanTracer LBx, PanTracer Tissue and RaDaR ST, electronic health record access through Epic Aura, research presentations using Oncology Data Solutions, and the operation of CAP-accredited and CLIA-certified laboratory capabilities in the United States and the United Kingdom.
NeoGenomics (NASDAQ: NEO) priced a private offering of $275 million 0.75% convertible senior notes due 2032 to qualified institutional buyers, with an option for an extra $41.25 million. The notes carry a 0.75% coupon and mature on July 1, 2032.
The initial conversion price is about $14.16 per share, a 35% premium to the $10.49 last sale price, and NeoGenomics entered capped call transactions capped at $20.98 per share. Net proceeds are estimated at $266.15 million, mainly to fund capped calls, repurchase $276 million of 2028 notes, and buy back up to $25 million of common stock.
NeoGenomics (NASDAQ: NEO) began a private offering of $275 million convertible senior notes due 2032 to qualified institutional buyers under Rule 144A. Initial purchasers may buy up to an extra $41.25 million. NeoGenomics plans capped call transactions, partial refinancing of 0.25% notes due 2028, potential $25 million share repurchases, and use of remaining proceeds for general purposes.
NeoGenomics (NASDAQ:NEO) will present eight oncology research abstracts at the ASCO Annual Meeting 2026, May 29–June 2 in Chicago (booth #32130).
Highlights include MRD and ctDNA advances, colorectal cancer RaDaR ST data with MD Anderson, new biomarkers for targeted therapies, and an AML MRD flow assay.
NeoGenomics (NASDAQ:NEO) announced participation in two upcoming investor events. The company will attend the 23rd Annual Craig-Hallum Institutional Investor Conference in Minneapolis with investor 1x1 meetings on Thursday, May 28, 2026.
NeoGenomics will also join the Jefferies Global Healthcare Conference 2026 in New York, hosting a fireside chat on Thursday, June 4, 2026 at 10:30 a.m. EDT, plus investor 1x1 meetings. A live webcast and replay will be available on its investor relations website.
NeoGenomics (NASDAQ: NEO) reported Q1 2026 results: consolidated revenue $187M (+11% YoY) and clinical revenue +14%, with NGS growth +26%. Adjusted EBITDA was $9M, net loss narrowed to $17M, and cash plus marketable securities totaled $146M. The company raised full‑year 2026 revenue guidance to $797–$803M. Key operational milestones include the commercial launch of RaDaR ST MRD, MolDX coverage for PanTracer LBx, and introduction of PanTracer Pro.
NeoGenomics (NASDAQ: NEO) announced integration of its full oncology testing portfolio with Epic Aura, enabling physicians to order tests and view results directly within the Epic EHR workflow. The integration covers solid tumor and hematologic malignancy tests and supports future delivery of liquid biopsy and MRD diagnostics. The company said this EHR access could drive a 20–30% increase in test adoption per site, improve scalability for health systems, and help shorten time to treatment by streamlining ordering and results delivery.
NeoGenomics (NASDAQ: NEO) will present eight posters and one oral presentation at the AACR Annual Meeting 2026 in San Diego, April 17–22, 2026, showcasing integrated clinical and genomic insights from its Oncology Data Solutions platform.
Presentations cover MRD in LA-HNSCC, multi-omic biomarkers, AI phenotyping, IHC and CGP applications; attendees can visit booth #1537 for more information.
NeoGenomics (NASDAQ: NEO) will report Q1 2026 financial results after U.S. market close on April 28, 2026. Management will host a webcast and conference call at 4:30 p.m. ET to discuss results and recent highlights.
The live webcast is available via the Investor Relations site at ir.neogenomics.com and will be archived for replay. Telephone access uses participant code 750346.
NeoGenomics (NASDAQ: NEO) announced that its PanTracer LBx liquid biopsy test received Medicare coverage through CMS MolDX under LCD L38043 on March 16, 2026. This decision enables Medicare patients to access a blood-based comprehensive genomic profiling option evaluating more than 500 genes, including MSI and bTMB, with a seven-day turnaround.
The test is performed in NeoGenomics' CLIA-certified California lab and can be ordered standalone, as a reflex, or concurrently with tissue testing, expanding access to precision oncology in community settings.
NeoGenomics (NASDAQ: NEO) launched RaDaR ST, a circulating tumor DNA (ctDNA) assay for detecting molecular residual disease (MRD) across multiple solid tumors. RaDaR ST tracks up to 48 tumor-specific variants with an LOD95 of 11 ppm, combines whole-exome sequencing and bioinformatics, and is validated in breast and HPV-negative head and neck studies. The assay is approved by Medicare for initial launch indications, with two additional reimbursement indications submitted. NeoGenomics cited a >$20 billion addressable MRD market growing ~30% annually and 10% current penetration.